Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary  advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI,  through the application of the Clarifi®  epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform. Clarifi ASD is now available through prescription; details on how to obtain testing are available on Clarifi’s website. 

Finally, we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.